Baxalta Company Profile (NYSE:BXLT)

About Baxalta

Baxalta logoBaxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: BXLT
  • CUSIP:
Key Metrics:
  • Previous Close: $46.02
  • 50 Day Moving Average: $46.02
  • 200 Day Moving Average: $46.02
  • 52-Week Range: $37.44 - $46.52
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 18.12
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Baxalta:

Analyst Ratings

Consensus Ratings for Baxalta (NYSE:BXLT) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Baxalta (NYSE:BXLT)
DateFirmActionRatingPrice TargetDetails
4/6/2016Cowen and CompanyReiterated RatingBuyView Rating Details
12/9/2015Barclays PLCBoost Price TargetEqual Weight$38.00 -> $40.00View Rating Details
10/27/2015William BlairReiterated RatingBuyView Rating Details
8/11/2015Credit Suisse GroupBoost Price TargetOutperform$37.00 -> $42.00View Rating Details
7/21/2015J P Morgan Chase & CoReiterated RatingHoldView Rating Details
7/16/2015Citigroup Inc.Initiated CoverageBuy$40.00View Rating Details
7/13/2015Deutsche Bank AGInitiated CoverageHold$32.00View Rating Details
7/6/2015Goldman Sachs Group, Inc. (The)Initiated CoverageHoldView Rating Details
7/1/2015Morgan StanleyInitiated CoverageEqual -> Equal Weight$35.00View Rating Details
(Data available from 2/25/2015 forward)


Earnings History for Baxalta (NYSE:BXLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/28/2016Q116$0.46$0.47$1.47 billion$1.50 billionViewN/AView Earnings Details
2/16/2016Q415$0.56$0.57$1.71 billion$1.80 billionViewN/AView Earnings Details
10/29/2015Q315$0.49$0.56$1.51 billion$1.60 billionViewListenView Earnings Details
7/30/2015Q215$0.49$0.40$1.41 billion$1.47 billionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Baxalta (NYSE:BXLT)
Current Year EPS Consensus Estimate: $2.19 EPS
Next Year EPS Consensus Estimate: $2.54 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.49$0.49$0.49
Q2 20161$0.54$0.54$0.54
Q3 20161$0.58$0.58$0.58
Q4 20161$0.59$0.59$0.59
(Data provided by Zacks Investment Research)


Current Dividend Information for Baxalta (NYSE:BXLT)
Annual Dividend:$0.00
Dividend Yield:0.00%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:0.00% (Based on Current Year Consensus EPS Estimate)
0.00% (Based on Next Year Consensus EPS Estimate)

Dividend History for Baxalta (NYSE:BXLT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Baxalta (NYSE:BXLT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2016Albert P L StrouckenDirectorSell5,660$39.98$226,286.80View SEC Filing  
2/25/2016Blake E DevittDirectorBuy5,900$39.17$231,103.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Baxalta (NYSE:BXLT)
News IconAnalysts Peer Into Their Crystal Balls For Baxalta Inc (NYSE:BXLT): Where Is It headed? - Winfield Review (NYSE:BXLT) - February 21 at 1:24 PM
News IconAre Analysts Optimistic About Where Baxalta Inc (NYSE:BXLT) is Heading? - Winfield Review (NYSE:BXLT) - February 19 at 3:51 PM
News IconEarnings in Full Force, Analysts Take Aim at Baxalta Inc (NYSE:BXLT) - Wall Street Beacon (NYSE:BXLT) - January 26 at 4:54 PM
News IconAre Analysts Predicting a Near-Term Upswing For Baxalta Inc (NYSE:BXLT)? - Wall Street Beacon (NYSE:BXLT) - January 24 at 4:38 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Baxalta Inc (NYSE:BXLT) - Wall Street Beacon (NYSE:BXLT) - January 17 at 4:52 PM
News IconWill The Needle Move For Baxalta Inc (NYSE:BXLT) Shares This Earnings Season? - Wall Street Beacon (NYSE:BXLT) - January 13 at 2:22 AM logoTakeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation (NYSE:BXLT) - January 9 at 5:14 PM logoCTI Biopharma stock revived after FDA ruling, reverse stock split (NYSE:BXLT) - January 6 at 9:27 PM
News IconPieris (PIRS) Teams up with Private Drug Maker for New Immunotherapies - Economic Calendar (NYSE:BXLT) - January 6 at 2:32 AM
News IconIn 3Q Report, Shire Breaks Out Data From Baxalta Acquisition and Announces Several Program Terminations - PharmaLive (press release) (subscription) (NYSE:BXLT) - November 1 at 4:02 PM logoShire reiterates full-year guidance after in-line Q3 (NYSE:BXLT) - November 1 at 4:02 PM logoShire slips on poor sales of haemophilia drugs (NYSE:BXLT) - November 1 at 4:02 PM logoHouston cancer company closes additional funding - Houston Business Journal (NYSE:BXLT) - October 10 at 3:54 PM
News IconMartin Whitman Exits Baxalta in 3rd Quarter - Yahoo Sports (NYSE:BXLT) - October 4 at 3:54 PM logoMairs and Power Buys Walt Disney, Exits Baxalta - (NYSE:BXLT) - September 28 at 8:47 AM logoJeff Auxier buys Biogen, LyondellBasell, Union Pacific (NYSE:BXLT) - September 19 at 4:51 PM logoShire plc -- Moody's assigns Baa3 to Shire's sr. notes; stable outlook (NYSE:BXLT) - September 16 at 3:56 PM
News IconDaniel Loeb Exits Amgen, Trims Dow Chemical - Yahoo Sports - Yahoo Sports (NYSE:BXLT) - September 7 at 10:03 AM logoTracking Stephen Mandel's Lone Pine Capital Portfolio - Q2 2016 Update - Seeking Alpha (NYSE:BXLT) - August 25 at 4:05 PM logoForm N-PX WELLS FARGO FUNDS TRUST For: Jun 30 - (NYSE:BXLT) - August 25 at 8:54 AM logoSteve Mandel Buys Shire, Axes 6 Positions in —nd Quarter - (NYSE:BXLT) - August 17 at 9:28 PM logoTracking Tweedy Browne Portfolio - Q2 2016 Update - Seeking Alpha (NYSE:BXLT) - August 12 at 12:40 PM logoBaxter International Inc. -- Moody's rates Baxter's new notes Baa2; outlook stable (NYSE:BXLT) - August 10 at 3:28 PM logoApple-Twitter: Why Not? - Seeking Alpha (NYSE:BXLT) - August 7 at 3:59 PM logo[$$] Shire lifts guidance as Baxalta spurs strong sales growth (NYSE:BXLT) - August 2 at 4:07 PM logoShire Says Baxalta Combination to Boost Profit and Sales (NYSE:BXLT) - August 2 at 8:51 AM logoShire upgrades Baxalta cost savings after Q2 earnings beat (NYSE:BXLT) - August 2 at 8:51 AM logoShire lifts earnings and Baxalta cost saving targets (NYSE:BXLT) - August 2 at 8:51 AM logo[$$] Shire Earnings: What to Watch (NYSE:BXLT) - August 1 at 4:00 PM logo3 Mutual Funds Focusing on Arbitrage Profits (MERFX, ARBFX) (NYSE:BXLT) - July 28 at 10:00 AM logoDan Loeb's Third Point tells why investing is like 'Game of Thrones' (NYSE:BXLT) - July 26 at 8:26 PM logoBaxter Beats Earnings Estimates, Raises Full-Year Guidance (NYSE:BXLT) - July 26 at 7:11 AM logoTweedy Browne Global Value Fund Makes Trades Around the World - Nasdaq (NYSE:BXLT) - July 13 at 3:59 PM logoBiotech ETF IBB Short Squeeze May Be Ahead - Seeking Alpha (NYSE:BXLT) - July 12 at 4:05 PM logoTweedy Browne Global Value Fund Makes Trades Around the World - (NYSE:BXLT) - July 12 at 4:05 PM logoTop 3 Stocks Hedge Funds Bought in Q1, 2016 (NYSE:BXLT) - June 21 at 10:00 AM logoTop 3 Stocks Hedge Funds Bought in Q1, 2016 (NYSE:BXLT) - June 21 at 10:00 AM logoAre Hedge Funds Trying to Catch the Falling Knife? (AMZN, NFLX) (NYSE:BXLT) - June 19 at 3:52 PM logoWhy Is Mylan So High on Trastuzumab Biosimilar Data? (NYSE:BXLT) - June 7 at 2:46 PM logoFitch Downgrades Baxalta to 'BBB'; Withdraws Ratings (NYSE:BXLT) - June 7 at 12:17 PM logoShire plc -- Moody's downgrades Baxalta to Baa3; stable outlook (NYSE:BXLT) - June 6 at 1:02 PM


What is Baxalta's stock symbol?

Baxalta trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXLT."

How often does Baxalta pay dividends? What is the dividend yield for Baxalta?

Baxalta announced a quarterly dividend on Tuesday, May 10th. Shareholders of record on Friday, June 10th will be given a dividend of $0.07 per share on Friday, July 1st. This represents a $0.28 annualized dividend and a dividend yield of 0.61%. The ex-dividend date of this dividend is Wednesday, June 8th.

How do I buy Baxalta stock?

Shares of Baxalta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Baxalta stock cost?

One share of Baxalta stock can currently be purchased for approximately $46.02.

Baxalta (NYSE:BXLT) Chart for Saturday, February, 25, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Baxalta (NYSE:BXLT)

Earnings History Chart

Earnings by Quarter for Baxalta (NYSE:BXLT)

Dividend History Chart

Dividend Payments by Quarter for Baxalta (NYSE:BXLT)

Last Updated on 2/25/2017 by Staff